INTRODUCTION

The worldwide prevalence of antibodies against hepatitis C virus (anti-HCV) in blood donors has been shown to range from 0.2% to 2.7% (2,3). On the other hand, the prevalence of anti-HCV varies from 1.0% to 3.0% in general population (1,9) and from 0 to 13% in pregnant women (3, 16, 17, 20, 22, 24, 25, 26, 29, 30, 33, 36).

In pregnant women, the diagnosis of hepatitis C virus (HCV) infection is particularly important to evaluate vertical transmission. The rate of neonatal transmission estimated in review articles varies from 4.5% to 6.0% (5, 8, 21, 31, 39). Even though while some authors were not able to find vertical transmission (10, 30), others found a transmission rate varying from 2.3% to 33% (4, 6, 11, 12, 15, 16, 17, 18, 20, 22, 23, 24, 25, 26, 27, 28, 32, 33, 34, 36, 37, 39).

Some authors found out that transmission could be increased in the presence of human immunodeficiency virus (HIV) coinfection (10, 27, 28, 35, 36, 37), while other authors did not (4, 5, 8, 16, 19, 39). Another factor that may be associated with increased transmission is the maternal viral load (4, 11, 14, 22, 24, 26, 34, 35), although there is no consensus on this subject. HCV genotype has also been investigated as a cause of increased transmission (18, 34, 35, 36, 39), but only one study (39) suggests this influence.

In Brazil, no studies concerning vertical transmission of HCV have been carried out. Thus, the objective of the present study is to assess the prevalence of anti-HCV in pregnant women and to determine the rate of vertical transmission.

PATIENTS AND METHODS

From August 1998 to November 1999, 1,090 consecutive pregnant women followed at the Prenatal Care Clinic at “Hospital Nossa Senhora da Conceição” were screened for anti-HCV. Those with a positive test result were invited to join the study.

A blood sample was collected, and the serum was separated into two aliquots: one was stored at -80 °C for further determination of hepatitis C virus ribonucleic acid (HCV RNA) presence, viral
load, and genotyping, and the other was used to investigate the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as well as the presence of antibodies against hepatitis B virus surface antigen (anti-HBs) and core antigen (anti-HBc). The screening for hepatitis B virus surface antigen (HBsAg) and antibody against HIV (anti-HIV) had been previously carried out as part of the hospital's prenatal care routine.

Mothers were considered HCV-infected when they were positive for anti-HCV and HCV RNA by polymerase chain reaction (PCR).

Patients who presented with a positive test for HCV RNA were followed during pregnancy. After delivery, one blood sample was collected from the newborn children within the 1st month of life, and a second one in the 6th month. Each sample was separated into two aliquots: one was stored at -80 °C for further HCV RNA identification, quantification, and genotyping, and the other was used to investigate the presence of anti-HCV and the levels of ALT and AST. The children were investigated for the presence of anti-HIV and for hepatitis B virus infection when their mothers were coinfectected.

The levels of AST and ALT were determined by commercial methods (AST FLEX™ and ALT FLEX™, AR model of the DIMENSION™ system, Dade Behring Inc., Newark, DE, USA). Anti-HIV was detected by the microparticle enzyme immunoassay (MEIA) (AxSYM™ HIV-1/HIV-2, Abbott Diagnostics Division, Illinois, USA) and by the immune chromatographic assay Determine™ HIV-1/2 (Abbott Diagnostics Division, Illinois, USA). Positive samples were submitted to confirmation testing by a cultured cell layer immunofluorescence test (“Fundação Oswaldo Cruz”, Rio de Janeiro, RJ, Brazil). Anti-HCV was detected by MEIA AxSYM™ HCV 3.0 (Abbott Diagnostics Division, Illinois, USA). HCV RNA was detected by PCR (HCV AMPLICOR™, Roche Diagnostics Systems, Inc., Branchburg, NJ, USA) and quantified by the branched desoxyribonucleic acid signal amplification test (b-DNA) (Quantiplex™ HCV RNA 2.0, Chiron Diagnostics, California, USA). The HCV genotyping was done by a direct sequencing method of the PCR AMPLICOR™ amplification products.

This study was approved by the hospital’s ethics committee. In addition, all the patients included in the study gave their written informed consent.

In the statistical analysis, average was used for demographic data and median was used for HCV viral load values because of the variation that was found.

The comparison between HCV/HIV-coinfected and non-coinfected patients was analysed by Kruskal-Wallis’s test, with a significance level of 5%.

RESULTS

Of 1,090 pregnant women surveyed, 29 were anti-HCV-positive, which means a prevalence of 2.66%. The anti-HCV test was carried out at 24.08 ± 8.95 weeks of pregnancy. To study vertical transmission, 25 patients who had a positive PCR result for HCV were assessed (8 with HIV coinfecion). The age average was 27.6 ± 7.07 years (17 to 42 years); 56% were Caucasian. No patient had hepatitis B positive serology or signs or symptoms of liver disease.

Median maternal HCV viral load was 3.132 ± 5.891 MEq/mL (mean = 5.139 ± 5.891 MEq/mL), ranging from <0.200 MEq/mL to 21.420 MEq/mL. In those HIV-coinfected mothers, median HCV viral load was 5.191 ± 4.476 MEq/mL (mean = 6.158 ± 4.476 MEq/mL) while in non-coinfected mothers, median was 2.459 ± 6.521 MEq/mL (mean = 4.659 ± 6.521 MEq/mL). These results did not present statistical difference (P = 0.116).

The most prevalent maternal genotypes were 3a (eight patients), 1b (seven patients) and 1a (six patients). Genotype 2b was observed in two patients, and genotype 3c, in one patient. One sample was not suitable for sequencing.

Three patients were excluded from the study: one of them had a miscarriage and two (HIV-coinfected) were lost during the follow-up period. The 22 patients who remained in the study (6 HIV-positive) were followed and gave birth to 23 children (one set of twins), 13 females and 10 males. Patients with HIV coinfection had a median CD4 count of 485.5 ± 267.2 cells/mm³ (varying from 307 to 1,030 cells/mm³).

Deliveries occurred at an average of 38.26 ± 2.94 weeks of pregnancy (30 to 42 weeks). There were 12 cesarean sections and 10 vaginal deliveries. Six children had an Apgar score below 8 at the 1st minute, but all 23 children presented an Apgar score above 8 at the 5th minute.

Blood samples were collected from 18 of the 23 children in the 1st month of life; all were positive for anti-HCV. Twenty-two children had their blood tested at the 6th month of life; anti-HCV was detected in seven cases (31.82%). Taking into consideration the 17 children who had two blood samples tested (at the 1st and 6th months of life), anti-HCV became negative in 58.82% at the age of 6 months.

Only one child, a girl born after vaginal delivery, presented positive PCR results at the 1st month of life, with a viral load of 41.570 MEq/mL and genotype 3a. That means a vertical transmission rate of 5.56% (1/18). By the age of 6 months, the blood of this child was tested again: anti-HCV was still present, but HCV RNA could not be detected by PCR. The AST levels of this child were normal in the 1st month (20 U/L) and elevated in the 6th month of life (55 U/L), when PCR did not detect HCV RNA anymore, being normal again in a future determination (12th month); ALT was always normal. Her mother was HIV-coinfected, with an HCV viral load of 3.765 MEq/mL and genotype 3a (the genotype homology with the child’s virus was 100%). All other children submitted to PCR tested negative at both ages.

DISCUSSION

The prevalence of anti-HCV in pregnant women (2.66%) was higher than the prevalence found (1.74%) for blood donors in the same hospital[2]. This was expected, since blood donors are a select group, not representative of the general population[14]. It was also higher than the percentages reported in most studies with pregnant women worldwide, which ranges from 0% to 1.26%(1, 4, 20, 22, 24, 25, 26, 30, 33), even though some investigators[16, 17, 29] have reported similar prevalences (1.7% to 2.6%).

It is important to realize that we did not observe significant differences in the HCV viremia detected in HIV-coinfected mothers and in non-coinfected ones, as corroborated by other authors[15, 19]. On the other hand, there are different opinions[16, 17], suggesting that a lower immunity induced by HIV allows a greater HCV viral load to exist. Even though, it is to be emphasized, that the HIV-coinfected patients evaluated in this study had a good immunologic status (median CD4 count of 485 cells/mm³).

It is widely accepted[4, 5, 10, 13, 17, 26, 27, 31, 34, 36, 39] that, in most of the children, anti-HCV passive antibodies will disappear in the first 12 months of life. We detected anti-HCV in all children tested at the 1st month. However, by the 6th month, 58.82% had negativated the anti-HCV, as expected.
A limited number of studies on vertical transmission of HCV showed a clear distinction between individuals with or without detectable HCV RNA \(^{20,24,32,33,39}\). Most of the studies were based only on the anti-HCV status of the patients, which may result in questionable rates. In the present study, only pregnant women who were HCV-positive by PCR were included \(^{17,23,28,34}\). This way, we found a vertical transmission rate of 5.56\% in which the presence of HCV RNA in the children’s blood samples was taken into consideration. This corresponds to the 4.5\% to 6\% rate reported in literature reviews \(^{7,8,21,31,38}\), as well as in other original papers \(^{6,25,37}\).

We should also consider the diagnosis criteria for this infection in children, since some authors considered a child as HCV-infected only when HCV RNA was detected in two or more occasions \(^{5,9,13,18,20}\), while others accepted as a criterion for vertical transmission the occurrence of at least one positive PCR sample at any time \(^{4,5,11,22,30,36}\). Since most of the studies do not follow the children for a long time after birth, SPENCER et al. \(^{13}\) suggest that this should be done in order to observe whether the viral clearance is transitory or permanent. In our study, the sample of the infected child was positive at the 1st month of life, and clearance occurred by the age of 6 months; this could be considered as a transient viremia by some authors \(^{5,20}\).

For several authors \(^{4,11,14,22,24,26,35,36}\), the viremia level of an HCV-positive mother is related to vertical transmission. However, other investigators do not agree \(^{5,13,17,20,28,29,36}\). Literature data are not consistent regarding HCV viral load determined by the bDNA technique as a risk factor for vertical transmission. OKAMOTO et al. \(^{20}\) found higher viral load values among mothers who transmitted the infection to their children than among those who did not. MORIYA et al. \(^{22}\) diagnosed vertical transmission only when the mother’s viral load was higher than 5.0 MEq/mL. However, ZANETTI et al. \(^{19}\), when comparing mothers who transmitted HCV and those who did not, found out that the HCV viral load was not different between the two groups. This result was corroborated by a more recent study carried out by the same group \(^{37}\). Also, other studies did not find out any difference concerning the viral load \(^{13,29}\). On the other hand, for PIPAN et al. \(^{29}\), vertical transmission was absent even when HCV RNA blood levels were above 1.0 MEq/mL.

In the case of vertical transmission observed in our study, the mother was HCV-coinfected and had a HCV viral load of 3.765 MEq/mL, which was not much higher than the 3.132 MEq/mL median value found for the whole group, though lower than the 5.191 MEq/mL median value observed for the HCV-coinfected mothers. Due to the fact that in our study only one case of vertical transmission was found, it is hard to draw any conclusion regarding the influence of maternal HCV viral load and HIV coinfection on vertical transmission of HCV.

Our case of vertical transmission occurred with an HIV-coinfected mother, which constitutes a situation considered to be relevant for the vertical transmission of HCV \(^{18,27,28,35,36,37}\).

Most of the studies investigating the correlation between HCV genotype and vertical transmission were not able to establish a clear association between both \(^{18,34,35,36,37}\). ZUCCOTTI et al. \(^{159}\), on the other hand, considered genotypes 1b and 3a more frequent in cases of vertical transmission, although they were also more prevalent in HIV-coinfected mothers; this could be seen as a bias in the experiment. Our study showed that vertical transmission occurred in an HIV-coinfected mother with genotype 3a, with 100\% of homology with that observed in her daughter; this could be taken as an indication of mother-to-child transmission route.

To summarize, though vertical transmission of HCV seems to be infrequent, except perhaps for HIV-coinfected mothers, we conclude that the prevalence of HCV infection in pregnant women should not be neglected. Thus, anti-HCV screening should be indicated in the prenatal care routine of pregnant women with risk behavior for HCV infection, mainly in the cases of those coinfected by HIV. Since we still do not have therapeutic measures or obstetric procedures to reduce the risk of vertical transmission of HCV, early diagnosis and follow-up of the infected children should be emphasized.
REFERENCES


